Association between Vγ2Vδ2 T cells and disease progression after infection with closely related strains of HIV in China

Clinical Infectious Diseases

Volumn 46, Issue 9, 2008, Pages 1466-1472

  Li, Haishan ^a,d   Peng, Hong ^a   Ma, Pengfei ^a   Ruan, Yuhua ^a   Su, Bing ^b   Ding, Xinping ^c   Xu, Chen ^c   Pauza, C David ^d   Shao, Yiming ^a,e  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Anhui Provincial Center for Disease Control and Prevention   (China)

^c Fuyang Center for Disease Control and Prevention   (China)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPENTENYL DIPHOSPHATE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD DONOR; CD4 LYMPHOCYTE COUNT; CELL FUNCTION; CHINA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS STRAIN; CD4+ T LYMPHOCYTE; CROSS-SECTIONAL STUDY; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CHINA; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 42549133680     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587107     Document Type: Article

References (25)

1. Evans PS, Enders PJ, Yin C, Ruckwardt TJ, Malkovsky M, Pauza CD. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology 2001; 104:19-27.
2. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994; 264:267-70.
3. Kaufmann SH. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci U S A 1996; 93:2272-9.
4. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995; 375:155-8.
5. Poccia F, Gougeon ML, Bonneville M, et al. Innate T-cell immunity to nonpeptidic antigens. Immunol Today 1998; 19:253-6.
6. Poccia F, Cipriani B, Vendetti S, et al. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes. J Immunol 1997; 159:6009-17.
7. Battistini L, Borsellino G, Sawicki G, et al. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol 1997; 159:3723-30.
8. Lang F, Peyrat MA, Constant P, et al. Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol 1995; 154:5986-94.
9. Poccia F, Battistini L, Cipriani B, et al. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis 1999; 180:858-61.
10. Tikhonov I, Deetz CO, Paca R, et al. Human Vgamma2Vdelta2 T cells contain cytoplasmic RANTES. Int Immunol 2006; 18:1243-51.
11. Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 2007; 215:123-35.
12. Chen ZW, Letvin NL. Vgamma2Vdelta2+ T cells and anti-microbial immune responses: microbes and infection. Microbes Infect 2003; 5:491-8.
13. Wallace M, Bartz SR, Chang WL, Mackenzie DA, Pauza CD, Malkovsky M. Gamma delta T lymphocyte responses to HIV. Clin Exp Immunol 1996; 103:177-84.
14. Autran B, Triebel F, Katlama C, Rozenbaum W, Hercend T, Debre P. T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol 1989; 75:206-10.
15. Poccia F, Boullier S, Lecoeur H, et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol 1996; 157:449-61.
16. Wallace M, Scharko AM, Pauza CD, et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med 1997; 3:60-71.
17. Xu JQ, Wang JJ, Han LF, et al. Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl) 2006; 119:1941-8.
18. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 2004; 189:1482-6.
19. Gan YH, Pauza CD, Malkovsky M. Gamma delta T cells in rhesus monkeys and their response to simian immunodeficiency virus (SIV) infection. Clin Exp Immunol 1995; 102:251-5.
20. Martini F, Poccia F, Goletti D, et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis 2002; 186:847-50.
21. Selin LK, Santolucito PA, Pinto AK, Szomolanyi-Tsuda E, Welsh RM. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001; 166:6784-94.
22. Li H, Deetz CO, Zapata JC, et al. Vaccinia virus inhibits T cell re ceptor-dependent responses by human gammadelta T cells. J Infect Dis 2007; 195:37-45.
23. Maloy KJ, Odermatt B, Hengartner H, Zinkernagel RM. Interferon gamma-producing gammadelta T cell-dependent antibody isotype switching in the absence of germinal center formation during virus infection. Proc Natl Acad Sci U S A 1998; 95:1160-5.
24. Hebbeler AM, Propp N, Cairo C, et al. Failure to restore the Vg2-Jg1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol (in press).
25. Gougeon ML, Malkovsky M, Casetti R, Agrati C, Poccia F. Innate T cell immunity to HIV-infection: immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? Vaccine 2002; 20:1938-41.